Introduction
It is well established that androgens are products of progestogen metabolism and act as an essential substrate for the production of estrogen via the 2-cell/two gonadotrophin model for estrogen biosynthesis (Hillier et al., 1994) . However, current understanding of the physiological role of androgens in ovarian function implies also the contribution of androgens to the paracrine regulation of follicular maturation and atresia . With respect to follicular function, androgens have been shown to exert both positive and negative actions, depending on experimental models. Most of our information regarding the actions of androgens as local regulators of ovarian function have been derived from murine studies. Interestingly, treatment with testosterone or dihydrotestosterone in intact rats leads to alterations in the cell cycle of granulosa cells and follicular atresia, while administration of an androgen antagonist to hypophysectomized animals, amplifies the stimulatory effects of FSH treatment thus indicating that endogenous androgens are antagonistic to gonadotrophinstimulated ovarian function (Zeleznik et al., 1979; Billig et al., 1993; Kaipia and Hsueh, 1997; Pradeep et al., 2002) . Thus, murine ovary studies led to the concept that androgens are atretogenic.
The above concept, however, cannot be extrapolated to primates and a series of recent studies in macaques has indicated that androgens appear to be positive regulators of follicular development and also show some synergistic effects with FSH on folliculogenesis (Hugues, 2005) . Remarkably, it has been reported that treatment of rhesus monkeys with dihydrotestosterone or testosterone augments follicular FSH receptor expression in granulosa cells (Weil et al., , 1999 , promotes initiation of primordial follicle growth and increases the number of growing pre-antral and small antral follicles . Besides these experimental data, further evidence for potential positive effects of androgens on follicular function comes from pharmacological or pathological models. Thus, polycystic ovary syndrome-like morphological and functional changes occur in women as a result of exposure to extraovarian androgens, as in congenital adrenal hyperplasia or androgen-producing tumors and in transsexual women treated with testosterone (Hugues, 2005) .
With this background, recent attempts of ovarian androgen priming have been developed on the basis that temporary exposure of follicles to increased levels of androgens may augment their responsiveness to FSH. LH, hCG, dehydroepiandrosterone, aromatase inhibitor and testosterone have been used mainly in the clinical setting of women with diminished ovarian reserve undergoing ovarian stimulation for IVF but results have been limited and inconclusive (Balasch et al., 2006; Barad and Gleicher, 2006; Massin et al., 2006; Durnerin et al., 2008; Lossl et al., 2008) .
In a previous prospective, self-controlled, proof-of-concept study including a case series of 25 very difficult responder patients who had two previous consecutive IVF cycles cancelled because of poor follicular response in spite of high-dose gonadotrophin ovarian stimulation and having normal basal FSH levels, we reported that treatment with transdermal testosterone preceding gonadotrophin therapy in the third IVF attempt increased up to 5-fold the number of recruited follicles in as much as 80% of patients (Balasch et al., 2006) . The purpose of this randomized clinical trial is to confirm and further evaluate the usefulness of pretreament with transdermal testosterone among lowresponder patients in an IVF general program.
Materials and Methods

Patients studied and design
From September 2006 to July 2007, a total of 62 infertile women who had a background of the first IVF treatment cycle cancelled at our fertility unit because of poor follicular response and fulfilling the inclusion criteria reported below were included in this study. In their second IVF treatment cycle patients gave informed consent to participate in the study, which was approved by the ethics committee of our hospital.
All the subjects were regularly menstruating (menstrual cycles of 25 -34 days) premenopausal women aged 31 -39 years at the time of their second IVF attempt and having a normal BMI of 19.3 -28.9 kg/m 2 . All the women had normal ovaries, no previous ovarian or pelvic surgery and normal ovulatory function according to mid-luteal serum progesterone concentrations and regular menses. None of them had endocrine or metabolic disorders, including polycystic ovarian disease. No patient had received any hormone therapy, including gonadotrophins, between the first and second IVF attempts. Patient indications for IVF included the following main diagnosis: male factor infertility, unexplained infertility, tubal infertility and minimal to mild endometriosis. In all patients, basal (cycle Day 2 -3) hormone measurements and antral follicle count were carried out in the cycle preceding IVF. Among 64 eligible patients asked to participate, 2 were excluded because of refusal to participate (Fig. 1) . The remaining 62 patients were randomized and received appropriate allocated intervention and were thus available for the final analysis of results. Patients were randomized in two treatment groups at the time of starting the second IVF attempt. Patients were allocated to each group according to a computergenerated randomization table. Sealed envelopes for the randomization list were used. In patients in Group 1 (n ¼ 31), transdermal application of testosterone preceding our standard gonadotrophin ovarian stimulation under pituitary suppression was used. In Group 2 (n ¼ 31 patients), controlled ovarian stimulation was carried out with high-dose gonadotrophin in association with a minidose GnRH agonist protocol. The latter has been, for years, the standard protocol for previous low-responder patients in our IVF program (Peñarrubia et al., 2005) and high doses of gonadotrophins have been used by the vast majority of authors and form a clear part of most protocols for ovarian stimulation in such patients (Tarlatzis et al., 2003; Klinkert et al., 2004) .
The sample size was based on two previous studies from our group showing that: (i) multifollicular development and oocyte retrieval was obtained in 80% of previous low responders receiving pretreatment with transdermal testosterone and gonadotrophin ovarian stimulation as used in patients in Group 1 (Balasch et al., 2006) ; and (ii) 46% of patients having their first cycle of IVF cancelled because of poor follicular response underwent oocyte retrieval in the second IVF attempt when treated according to the approach used in Group 2 (Peñarrubia et al., 2005) . The sample size required to provide power of 80% to detect this magnitude of treatment effect between groups was calculated to be 31 patients per group, using a two-tailed analysis with a detection limit of 5% of avoiding a type I error in hypothesis testing.
Ovarian stimulation regimens
Ovarian stimulation protocols used in the first (cancelled) IVF cycle and in both treatment groups for the specific purposes of the current investigation were as follows. In the first IVF treatment cycle we used recombinant human (r-h) FSH under pituitary suppression with GnRH agonist according to a routinely used protocol. Briefly, pituitary suppression was achieved by s.c. administration of leuprolide acetate (Procrin; Abbott Laboratories, Madrid, Spain). This treatment was started in the mid-luteal phase of the previous cycle and given 1 mg daily, then reduced to 0.5 mg after ovarian arrest was confirmed and continued until the administration of hCG. Gonadotrophin stimulation of the ovaries was started when serum estradiol (E 2 ) concentrations declined to ,50 pg/ml and a vaginal ultrasonic scan showed an absence of follicles .10 mm diameter. On Days 1 and 2 of ovarian stimulation, 450 and 300 IU per day of r-hFSH (Gonal-F, Serono S.A., Madrid, Spain), respectively, were administered subcutaneously. On Days 3 and 4 of ovarian stimulation, 150 IU per day of r-hFSH were administered to each patient. From Day 5 onward, r-hFSH was administered on an individual basis according to the ovarian response as assessed by sequential transvaginal ultrasonography and serum E 2 measurements.
In their second IVF attempt, patients in Group 1 received exactly the same standard long down-regulation protocol (including gonadotrophin type and dose on Days 1 -4 of ovarian stimulation) used in their first IVF treatment cycle but now including testosterone therapy during the 5 days preceding gonadotrophin treatment. Testosterone therapy was commenced the day when pituitary-ovarian suppression was confirmed. Transdermal testosterone treatment was carried out using a daily single patch with a 2.5 mg/day nominal delivery rate of testosterone (Androderm 2.5 mg, Cepa Schwarz Pharma, Madrid, Spain) which was applied on the thigh at night and removed always at 09.00 h in the morning. This transdermal delivery system maintains stable testosterone levels within narrow ranges with little within-and between-subject variation, provide a highly controllable way of delivering testosterone reliably, and the hormonal dose administered can be modified according to the duration of patch application (Buckler et al., 1998; De Sanctis et al., 1998; Mazer, 2000) . We chose to use testosterone 20 mg/kg per day for 5 days on the basis of previous experimental studies in primates . Thus, in each patient, the patch was applied at night at a time aimed to leave it in place for a predetermined number of hours in order to provide the desired daily dose of testosterone (e.g. in a woman weighing 60 kg and needing 1200 mg/day, the patch was used for 12 h [0.1 mg/h delivery rate Â 12 h ¼ 1.2 mg or 1200 mg] and thus applied at 21.00 h). Gonadotrophin ovarian stimulation was started the day following last testosterone patch application.
In the second IVF treatment cycle, patients in Group 2 received 0.5 mg/ day of leuprolide acetate from the mid-luteal phase of the previous cycle until pituitary suppression was achieved and then 0.25 mg/day thereafter. On Days 1 and 2 of ovarian stimulation, 300 IU per day of r-hFSH (Gonal-F, Serono S.A.) were administered together with four ampoules of hMG (75 IU FSH and 75 IU LH per ampoule; Menopur, Ferring S.A., Madrid, Spain) given i.m. On Days 3 and 4 of ovarian stimulation, four ampoules per day of hMG were administered to each patient. From Day 5 onward, hMG was administered on an individual basis according to the ovarian response.
The criteria for hCG administration (250 mg s.c.; Ovitrelle, Serono S.A.) were the presence of two or more follicles !18 mm in diameter with !4 follicles measuring !14 mm in association with a consistent rise in serum E 2 concentration. The cycle was cancelled when there were less than 3 follicles with diameter !14 mm after 8 -9 days of gonadotrophin therapy or after 4-5 additional treatment days without attaining, or the imminent prospect of attaining, the criteria for hCG administration. The cancellation of the cycle due to insufficient follicular growth or collection of 3 oocytes at retrieval defined the low-responder patient.
Oocyte aspiration was performed with vaginal ultrasonography 35-36 h after hCG administration. Embryo grading was recorded according to published criteria (Veeck, 1999) ; embryos of grades 1 or 2 were considered high quality. Two to three days after oocyte recovery, up to three embryos per patient (depending on the age of the patient, the indication for IVF and the number and quality of embryos available per replacement) were replaced. The luteal phase was supported with vaginal micronized progesterone (600 mg/day given at 8-h intervals) starting on the day following oocyte aspiration and continuing either up to menstruation or, if the patients became pregnant, for at least the first 3 weeks of pregnancy. Pregnancy was diagnosed by increasing serum concentrations of b-hCG Figure 1 Flow diagram for study of the usefulness of pretreatment with transdermal testosterone in low-responder IVF patients.
Androgens for low responders in IVF after embryo transfer, and the subsequent demonstration of an intrauterine gestational sac by ultrasonography.
Outcome measures
The primary end-point was the incidence of low-responder patients. Secondary outcomes included mainly the incidence of patients reaching ovum retrieval but also standard parameters of gonadotrophin treatment and ovarian response in IVF cycles (days of ovarian stimulation; dose of gonadotrophins; number of follicles, E 2 serum levels and endometrial thickness on hCG day, oocytes retrieved and embryos obtained). In addition, the implantation and pregnancy rates were also recorded and analyzed.
As both previous poor response to ovarian stimulation and raised basal FSH are markers of reduced ovarian reserve, we sought to determine whether elevated basal serum FSH may be an effect modifier on the potential usefulness of testosterone pretreatment in improving the ovarian sensitivity to FSH. Thus, patients in both groups were subdivided according to their basal FSH level: normal FSH concentration (,10 IU/l) and high FSH concentration (!10 IU/l). This threshold value was selected because, according to previous studies in our IVF program where receiveroperating characteristic analysis was used (Creus et al., 2000) , it is the best value for basal FSH in predicting ovarian response.
Hormone analyses and ultrasonography
Hormones were measured using commercially available kits. E 2 concentrations in serum were estimated by a competitive immunoenzymatic assay (Immuno 1, Technicon; Bayer, Tarrytown, NY, USA). The sensitivity was 10 pg/ml and the inter-assay coefficient of variation (CV) was 5%. FSH and LH serum concentrations were measured by an immunoenzymatic assay with two monoclonal antibodies (Immuno 1, Technicon; Bayer) and data expressed in terms of IRP 78/549 and 68/40, respectively. The sensitivity of the assays was 0.1 IU/l for FSH and 0.3 IU/l for LH, and inter-assay CV were 2.7 and 3.1%, respectively. Total b-hCG was measured by a solid-phase, two-site chemiluminiscent enzyme immunometric assay standardized against the Third International Standard 75/ 537 (Immulite, Diagnostic Products Co., Los Angeles, CA, USA), with a detection limit of 2 IU/l. The inter-assay CV was 5.8%.
Ultrasonic scans were performed using a Toshiba Eccocee SAA-340A/ EF unit (Toshiba Co., Tokyo, Japan) equipped with a 5 -7 MHz endovaginal probe (PVF-641VT) as previosly reported (Balasch et al., 2006) . The numbers of follicles in both ovaries were added for the total antral follicle count. The follicles visualized and counted by transvaginal sonography in the early follicular phase were 2-10 mm in size. This is based on the finding that follicle size can vary up to 10 mm before the dominant follicle is identified and, by including follicles up to 10 mm, the antral follicle cohort is determined at its maximal size (Pache et al., 1990; Scheffer et al., 1999) . The limit of sensitivity was 2 mm.
Statistical analysis
Data were analyzed by Statistical Package for the Social Sciences (SPSS) statistical software using the Mann -Whitney U-test and the chi-squared test as appropriate. Results are expressed as mean + SD. P , 0.05 was considered significant.
Results
As presented in Table I , the main demographic and baseline characteristics of the patients in Groups 1 and 2 were very similar, including age, BMI, causes and duration of infertility, basal FSH, LH, and E 2 serum levels, and the antral follicle count at baseline. This supports the validity of the randomization process. Analysis of gonadotrophin treatment and ovarian response shows that both the duration of gonadotrophin ovarian stimulation and the total amount of gonadotrophin used were significantly lower in Group 1 while the number of lowresponder patients was significantly lower [32.2 versus 71%; 95% confidence interval (CI) for the difference, 15.7 -61.6; P , 0.05], and the proportion of patients undergoing ovum retrieval tended to be higher, albeit not statistically different, in this treatment group. No significant differences were found for any of the remaining variables investigated. Data regarding oocyte retrieval and IVF outcome were similar in both treatment groups (Table II) .
A subsequent comparison was performed between patients having normal or high basal FSH level and according to treatment group allocation. In patients having normal basal FSH, there was an equal distribution between treatment groups for age, BMI, duration and cause of infertility and basal hormone levels and antral follicle count (Table III) . In such a subpopulation of patients, testosterone supplemented cycles showed a significant reduction in the duration of ovarian stimulation, total dose of gonadotrophin administered and number of low responders (37.5 versus 76.4%; 95% CI for the difference, 7.7-70.1; P , 0.05), while the proportion of patients undergoing hCG injection and oocyte retrieval was significantly higher in this treatment group (Table IV, Fig. 2 ). As presented in Table V , baseline characteristics were also similar for patients having high basal FSH and allocated in treatment Groups 1 or 2. Testosterone treatment in such patients was associated with a significant reduction in the duration and total dose of gonadotrophin treatment but the proportion of patients reaching ovum retrieval was similar in both treatment groups. However, the number of patients having a low response tended to be lower in Group 1 than in Group 2, the difference almost reaching statistical significance (26.6 versus 64.2%; 95% CI for the difference, 3.9-71.2; P ¼ 0.06) (Table VI, Fig. 2 Antral follicle count 4.7 + 1.7 4.1 + 1.4
Values are mean + SD unless specified otherwise. Between group differences all non-significant at 0.05 level of significance. E 2 , estradiol.
No adverse effect, systemic or on application site of the testosterone patch, was reported and no other practical difficulties related to the specific purposes of this study were encountered.
Discussion
This study is the first randomized clinical trial showing that pretreatment with transdermal testosterone may improve ovarian response to FSH in previous low-responder IVF patients. This is supported by our results showing that testosterone treatment significantly reduced the number of low responders in Group 1. Remarkably, control patients (Group 2) were treated with high-dose FSH/HMG and a 50% reduction in the standard dose of leuprolide acetate, which are both measures widely used for treatment of low-responder patients in an attempt to increase not only FSH but also LH effects on the ovaries acting through both exogenously administered and endogenous gonadotrophins (Davis and Rosenwaks, 1996; Tarlatzis et al., 2003) . In spite of this, the number of patients undergoing ovum retrieval was higher in Group 1 than in Group 2, while the duration of the gonadotrophin therapy and the amount of gonadotrophin needed to achieve the criteria for hCG injection were significantly lower in Group 1. The beneficial effect of testosterone application on the ovarian response was clearly evidenced among patients having normal basal FSH levels but testosterone pretreatment seems to make FSH therapy more efficient also in patients with high basal FSH concentrations as evidenced by a shorter duration of gonadotrophin treatment and lower total dose of gonadotrophin used as well as a decrease in the number of cycles with low response. However, the fact that, for women having increased basal FSH, the proportion of patients reaching ovum retrieval was the same in both treatment groups, suggests that the potential beneficial effect of testosterone treatment may be significantly modified in such a subpopulation of patients. This is in line with previous studies showing that the impaired reaction to ovarian stimulation with gonadotrophins in these 'expected' low responders (i.e. defined as patients estimated to have a high probability of poor response because of elevated FSH levels) is likely to be caused by a decline of the quantity of the oocyte pool, which parallels a decrease in quality (Klinkert et al., 2004) . The average antral follicle count of 4 -5 follicles found in our patients is also indicative of a low-responder patient as previously reported Androgens for low responders in IVF (Klinkert et al., 2005) . This cannot be overcome by transdermal testosterone application preceding gonadotrophin treatment. Although the division between normal and elevated FSH was done after the randomization and therefore introduces a non-truly randomized comparison, the threshold value for basal FSH in the current study was established according to data from our own laboratory and IVF program as recommended (The Practice Committee of the American Society for Reproductive Medicine, 2006) and is in keeping with common criteria for ovarian reserve evaluation (The Practice Committee of the American Society for Reproductive Medicine, 2006) .
Our study has several strengths. We included an homogeneous study population on the basis that all patients received their IVF treatment at our infertility unit and all of them had their first treatment cycle cancelled because of poor follicular response according to wellestablished and previously reported criteria. This avoids possible bias from the use of different approaches for ovarian stimulation and/or criteria for cycle cancellation. In the first IVF cycle, patients in Groups 1 and 2 were treated with a step-down regimen of r-hFSH, which maximizes the recruitment of follicles from the gonadotrophinsensitive pool and has proved to be clinically efficacious (Davis and Rosenwaks, 1996; Peñarrubia et al., 2005; Balasch et al., 2006) . This vigorous gonadotrophin ovarian stimulation was increased further in the second IVF cycle in patients in Group 2. While a universally accepted definition for the low-responder patient is not currently available (Tarlatzis et al., 2003) , the collection of 3 oocytes at retrieval or cancellation of the cycle due to insufficient follicular growth (,3 developing follicles in response to exogenous gonadotrophins) is the most widely used definition of low response and it was used in many other studies because of the poor prognosis in such cases (Hanoch et al., 1998; Hugues and Cedrin-Durnerin, 1998; Surrey et al., 1998; De Placido et This is based on the fact that, from a practical point of view, it is considered that four oocytes are needed to reach an average of two embryos available for transfer (Bancsi et al., 2002; Klinkert et al., 2004) . Finally, the use of the same and well-standardized IVF/ICSI laboratory techniques during the short time frame of this single-center study (10 months) precludes any bias in this respect. In fact, no changes were made during the study time on culture media, laboratory practice, or laboratory personal or equipment.
There were several potential limitations to this study. There was a higher than expected rate of patients undergoing ovum retrieval in the control group (58% rather than the 46% that was used in the power calculation). Hence, the study may have failed to detect a difference in cycle cancellation rates between Groups 1 and 2, but a clear trend in favor of the pretreated testosterone group was observed and the number of low responders was significantly reduced in Group 1. It could be argued that changes in down-regulation (use of daily minidose GnRH agonist) and gonadotrophin (higher doses of gonadotrophins including a HMG preparation) protocols in the study cycle in patients in Group 2 as compared with Group 1 can obscure the potential positive effect of testosterone treatment on outcome measures. However, several aspects deserve comment in this respect. First, our sample calculation was based on the cancellation rate obtained in our IVF program in previous low responders receiving the same approach applied to patients in Group 2 in the current investigation (Peñarrubia et al., 2005) . Second, we have previously reported that the history of an IVF cancelled cycle due to poor follicular response in our standard stimulation protocol reported above is a better predictor of cancellation in subsequent treatment cycles than age or basal FSH and this is true whatever the level of FSH (Peñarrubia et al., 2005) . Thus, we would be committing our patients to a poor outcome if we proceeded with the same approach in the second IVF cycle for the specific purpose of this investigation and this would not be accepted by our ethical committee. Finally, both results in the current investigation and our previous self-controlled, proof-of-concept study (Balasch et al., 2006) showing that testosterone therapy may improve ovarian response to gonadotrophins in women having been low responders when treated with the same highdose gonadotrophin stimulation protocol used in patients in Group 2, further reinforce the idea that testosterone pretreatment is a useful tool in such patients.
On the other hand, it could be postulated that the difference in total amount of gonadotrophins used between Groups 1 and 2 might be the consequence of preferring higher starting and maintenance doses of gonadotrophins in Group 2 rather than the effect of testosterone treatment on FSH action in Group 1. However, this is unlikely considering that daily doses of gonadotrophins were administered on an individual basis according to the ovarian response from stimulation Day 5 onwards, and not only the amount of gonadotrophin used was significantly lower in Group 1 but also the duration of gonadotrophin therapy was significantly shorter in this testosterone pretreated group. Similarly, it could be argued that the hCG/LH activity contained in the HMG preparation may have altered the ovarian response profile, as suggested in a recent study concluding that, at an equal dose, HMG displays a milder stimulation pattern than r-hFSH in terms of follicular development and E 2 serum levels (Hompes et al., 2008) . In that study, however, a fixed low gonadotrophin dose was used in first-cycle IVF normogonadotropic patients Values are mean + SD unless specified otherwise. Between group differences all non-significant at 0.05 level of significance.
on the basis that fixation of the dose allows an unbiased comparison of the stimulation characteristics of both gonadotrophin preparations (Hompes et al., 2008) . That scenario is very different from the current investigation dealing with patients having their first IVF treatment cancelled because of poor follicular response. In this study where vigorous gonadotrophin ovarian stimulation and flexible gonadotrophin dosages were used, follicle number and size as well as E 2 serum levels on the day of hCG injection were similar in Groups 1 and 2 but this was at the expense of longer duration of ovarian stimulation and higher total gonadotrophin consumption in Group 2. Follicular recruitment takes place in the early follicular phase and thus, during the stimulation process, both the timing and dose of gonadotrophin administered determine the number of follicles recruited and selected. Therefore, while the relatively modest starting (and strict fixed) dose used in that previous report (Hompes et al., 2008) allowed one to maximize any apparent difference between the two gonadotrophin preparations, the initial loading gonadotrophin dose used in both treatment groups in our study is probably optimal to stimulate the development of the follicle cohort in different patient types, although it will be of more advantage to some patients than others. In addition, while some prospective studies in low responders demonstrated significant benefits with r-hFSH (Raga et al., 1999; De Placido et al., 2000) , other investigators reported that the association of LH activity in the form of hMG (Meo et al., 2002) or r-hLH (Laml et al., 1999; Lisi et al., 2001) to r-hFSH during ovarian stimulation for assisted reproduction treatment improves success rates in previous low responders or in patients with reduced ovarian reserve. Recent studies using LH, hCG or aromatase inhibitor to increase the local, intraovarian levels of androgen prior to gonadotrophin ovarian stimulation for IVF failed to show a clear clinical benefit of androgen priming (Durnerin et al., 2008; Lossl et al., 2008) . Thus, it could be postulated that a more systemic approach with administration of testosterone as done in the current study represents a more efficient tool for ovarian androgen priming. This would be in line with previous work in monkeys Weil et al., 1999) and humans (Balasch et al., 2006) indicating that androgens may exert a positive effect on the process of follicular growth. This notwithstanding, from our study we cannot conclude as to whether the intraovarian androgen level was increased during the priming period and whether the granulosa cell FSH receptor level was enhanced. In this regard, it is important to note that interspecies differences might exist in ovarian androgen receptor location and expression, even between primates .
On the other hand, the short-term low-dose testosterone treatment used in this study was selected arbitrarily on the basis of a series of experiments in monkeys showing that androgens enhance follicular growth and survival Weil et al., 1998 Weil et al., , 1999 . However, the daily dose, timing and duration of androgen supplementation may be critical to adequately stimulate folliculogenesis mainly considering a recent study in rhesus monkeys showing that chronic administration (for 5 days before and continuing throughout FSH and LH treatment) of high dose of androgens is antagonistic to gonadotrophin-stimulated ovarian function in primates (Zeleznik et al., 2004) . It has been postulated that there is a threshold effect of androgens on follicular function such that antagonistic actions of androgens may be manifested at elevated concentrations. Also, there seem to be concentration-dependent interactions between FSH and testosterone, such that the ability of testosterone to interfere with FSH-stimulated ovarian function may be overridden by elevated levels of FSH (Zeleznik et al., 2004) .
Therefore, while beneficial effects of up-regulated androgen drive upon folliculogenesis seem to exist, data on the dose -response effects of androgen are not available and thus, the importance of determining the appropriate dose and timing for androgen administration cannot be overstressed. This aspect deserves further research considering also that in a previous randomized clinical trial, no beneficial effect of testosterone application on the ovarian response to FSH could be demonstrated in previous low responders (Massin et al., 2006) . In that previous study, the daily dose of testosterone was much higher and the duration of androgen therapy much longer (10 mg/day during 15 days prior to FSH treatment and irrespective of woman's BMI) than in our study. In addition, there were some other important methodological differences between the current investigation and that previous study (Massin et al., 2006) . Thus, in the previous report, low response was defined as peak E 2 levels ,1200 pg/ml and number of total retrieved oocytes 5 in a previous cycle, patients had evidence for decreased ovarian reserve according to Day 3 hormonal measurements, and they were given either GnRH agonist or antagonist in association with oral contraceptives. Therefore, overall, our study included a much more homogeneous study population which, in addition, was treated in an homogeneous way within each treatment group. The study by Massin et al. (2006) , but not ours, was a double-blind study. However, considering that: (i) all patients included in the current investigation had their first IVF cycle cancelled because of low response, (ii) the ovarian response to gonadotrophin stimulation is clearly and objectively evaluated by ultrasonography and serum E 2 measurements and (iii) patients were Values are mean + SD unless specified otherwise. Between group differences all non-significant at 0.05 level of significance.
treated with exogenous gonadotrophins under long-term pituitary suppression, any potential bias, if any, related to the unblinded design of this study seems negligible.
In conclusion, pretreatment with transdermal testosterone may improve the ovarian sensitivity to FSH and follicular response to gonadotrophin treatment in previous low-responder IVF patients. This approach leads to an increased follicular response compared with a high-dose gonadotrophin and minidose GnRH agonist protocol, but further studies including a larger number of subjects are necessary to show that the improved ovarian response implies a better probability of pregnancy in those patients. Also, further work is warranted in order to clarify whether the potential beneficial effect of testosterone treatment may be lessened or not in low-responder patients having elevated basal FSH levels. 
